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| INTRODUC TI ON
Fibroblast growth factor (FGF) 23 is a member of the FGF19 subfamily of FGFs, which is mainly secreted by osteocytes and osteoblasts, and is part of the systemic circulation.
1,2 Human FGF23 is a 32 kD protein, which consists of 251 amino acids and includes a signal peptide composed of 24 amino acids in the N-terminal portion of the protein 3 that works as an inhibitor of bone mineralization. 4, 5 FGF23 can suppress phosphate reabsorption and 1,25(OH)2D in the kidney, 6, 7 and FGF23 null mice show high serum phosphate levels with increased renal phosphate reabsorption and growth retardation with an abnormal bone phenotype. 8 Moreover, FGF23 treatment in rat calvaria (RC) cells and MC3T3.E1 can negatively regulate both differentiation and matrix mineralization through the interaction of FGF23 with FGFR1c. 9, 10 The data suggest that FGF23 functions as an endocrine factor and has direct effect on bone.
Mandibular prognathism is a maxillofacial disorder characterized by overgrowth of the mandibular bone. 11 Our previous study reported genome-wide linkage and whole-exome sequencing analyses on an MP pedigree, and in three unrelated MP patients, we discovered a mutation of FGF23 c.35C>A. 12 The treatment of mandibular prognathism in clinical includes orthodontic therapy and orthognathic surgery. Both of them involve bone remodelling which lead us to consider how mutant hFGF23 would affect bone remodelling during treatment.
In this study, we used osteoblasts to evaluate the direct function of FGF23 (A12D) in bone development. We determined that hFGF23(A12D) inhibited proliferation of RC cells and stimulated the differentiation of RC cells to osteoblasts through activating the mitogen-activated protein kinase (MAPK) signalling pathway via interactions with the intracellular domain of FGFR3.
| MATERIAL S AND ME THODS

| Lentiviral construction and preparation
The open reading frame (ORF) of wild or mutant human FGF23
was cloned into the pLVX-mCMV-ZsGreen plasmid (Viraltherapy Technologies, Wuhan, China).
Subsequently, lentiviruses
(rLV-hFGF23(A12D)-mCMV-ZsGreen and rLV-hFGF23-WTmCMV-ZsGreen) were prepared by transfection of plasmids (pLVXhFGF23-mCMV-ZsGreen and pLVX-hFGF23(A12D)-mCMV-ZsGreen)
into 293 T cells. Lentivirus (rLV-mCMV-ZsGreen) was used as a control.
| Isolation, infection and induction of RC Cells
Male Sprague Dawley (SD) rats were purchased from the Shanghai SLAC Laboratory Animal Co. Ltd. Primary RC cells were isolated from 24-hour-old SD rats. Briefly, calvariae were dissected and sectioned into fractions. After digestion with type II collagenase (Sigma-Aldrich, St. Louis, MO, USA) for 1 hour, calvariae fractions were placed into 6 cm cell culture dishes containing alpha-modified Eagle's medium (α-MEM;
Hyclone, Logan, UT, USA) supplemented with 12% foetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin/streptomycin. The third passages of RC cells were trypsinized and cultured at 0.5 × 10 4 / cm 2 in the same medium. When cells reached 70% confluency, they were infected with three lentiviruses (rLV-hFGF23(A12D)-mCMVZsgreen, rLV-hFGF23-WT-mCMV-Zsgreen and rLV-mCMV-ZsGreen) at a multiplicity of infection of 60 pfu/cell in the same medium containing 5 μg/mL polybrene (Sigma-Aldrich). Some cells were infected on day 15.
Rat calvaria cells infected with lentivirus were cultured in α-MEM supplemented with 10% FBS and 1% P/S additionally with 50 μmol/L ascorbic acid (Sigma-Aldrich), 10 mmol/L β-glycerophosphate (SigmaAldrich) and 100 nmol/L Dexamethasone (Sigma-Aldrich). In some cultures, SCH772984, SB203580 and AZD4547 (Selleck Chemicals, Houston, TX, USA) or vehicle (DMSO) were added from the fifth day.
| Enzyme-linked immunosorbent assay
After the cells were infected and osteogenically induced, conditioned media were collected and stored at −80°C until use. FGF23
was determined using the human FGF23 enzyme-linked immunosorbent assay (ELISA) kit (BiotechWell, Shanghai, China), according to the manufacturer's instructions.
| Cell proliferation assay
Cell proliferation was measured using the Cell Counting Kit-8 (Beyotime, Shanghai, China). Briefly, cells were trypsinized and cultured in a 96-well plate (0.3 × 10 4 /cm 2 ) and then infected with rLV-mCMV-ZsGreen, rLV-hFGF23(A12D)-mCMV-ZsGreen and rLV-hFGF23-WT-mCMV-ZsGreen. Cells were incubated with 10 µL CCK-8 per well for 1 hour and then measured at a 450 nm wavelength using an absorbance reader (ELx800; Bio-tek Inc, Winooski, VT, USA).
| Alkaline phosphatase staining and quantification
Alkaline phosphatase staining was performed using the Alkaline Phosphatase Staining Kit (Beijing Leagene Biotechnology, Beijing, China), according to the manufacturer's instructions. Images were captured, and the number of ALP+ cells in each well was counted using a stereomicroscope (EVOS; Thermo Fisher Scientific, Inc, Beijing, China).
The quantity of alkaline phosphatase was evaluated by the Alkaline Phosphatase Assay Kit (Nanjing Jiancheng, Nanjing, China), and the total protein concentration was determined using a BCA protein assay kit (Beyotime), according to the manufacturer's instructions.
| Alizarin red staining
Cells were stained in Alizarin red staining solution (Cyagen Biosciences, Suzhou, China), according to the manufacturer's instructions, and images were taken with a stereomicroscope.
Subsequently, cells were submerged in 1 mL 10% hexadecylpyridinium chloride for 30 minutes at 37°C. Finally, a microplate reader was used to measure the absorbance at 562 nm.
| RNA extraction and real-time PCR analysis
Total RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to manufacturer's instructions.
After detection of the concentration and purity of total RNA with the spectrophotometer (Nanodrop, Thermo Fisher Scientific), the RNA was reverse-transcribed to cDNA using a Prime-Script RT reagent kit (Takara Bio, Dalian, Japan) at 37°C for 15 minutes, then 85°C for 5 seconds. Real-time PCR was performed with the Applied Biosystems 7300 Real-Time PCR Systems (Thermo Fisher Scientific) using SYBR green (SuperReal PreMix Plus, SYBR Green; TIANGEN, Beijing, China), according to the manufacturer's directions. Primers (Table 1) were synthesized commercially (Sangon, Shanghai, China).
The products were verified by melting curve analysis, and the relative gene expression levels were calculated by the 2 −ΔΔCT method.
| RNA sequencing
Total RNA was extracted with the TRIzol reagent on the ninth day of osteogenic induction. First, we checked total RNA quality.
Subsequently, mRNA was purified with oligo-dT, and the retrieved RNA was fragmented to obtain 100-300 bp fragments. The first and second cDNA strands were synthesized. Double-strand cDNA was purified with magnetic beads and resolved in elution buffer for end repair and adenylated 3′ ends. After ligating adapters and performing size selection, the products were amplified to build the cDNA library. Sequencing was performed by the Illumina Hiseq 2500
(Illumina Inc, CA, USA) after a library quality check. Cuffdiff software was used to analyse the differential expression, and P < 0.05, |log2 (fold change)|>1 and q value <0.05 were considered significant.
| Bioinformatics prediction
The secondary structures of hFGF23(A12D), hFGF23-WT and 
| Transient transfection of 293 T cells
The ORFs of mutant hFGF23(A12D) with the HA-tag and FGFR3
(Protein Kinases; catalytic domain, PKCD) with the MYC-tag were cloned into a pcDNA3.1 plasmid (Viraltherapy Technologies).
Briefly, 293 T/RC cells were grown in a 10 cm cell culture dish, and transient transfection was performed using Lipofectamine™ 
| Immunofluorescence staining
Cells were washed three times with cold PBS and fixed in 4% para- 
| Co-immunoprecipitation
| Western blotting
Cells were lysed in cold RIPA buffer with protease inhibitors After washing three times with TBST, membranes were incubated for 1 hour at room temperature with secondary antibodies. Finally, membranes were washed three times with TBST, and data were captured with a chemiluminescence detection system (GE AI600, Boston, MA, USA).
| Statistics analysis
All data were analysed by one-way ANOVA and independent t tests.
P < 0.05 was considered significant.
TA B L E 1 Primer sequence for real-time PCR
Gene Primers
ALP-F TCCCAAAGGCTTCTTCTTGC ALP-R ATGGCCTCATCCATCTCCAC BMP-2-F GAAGCCAGGTGTCTCCAAGAG BMP-2-R GTGGATGTCCTTTACCGTCGT COLI(α)-F CTGCCCAGAAGAATATGTATCACC COLI(α)-R GAAGCAAAGTTTCCTCCAAGACC
FGF23-F TTGGATCGTATCACTTCAGC
FGF23-R TGCTTCGGTGACAGGTAG
FGFR3-F AGTGTGCGTGTAACAGATG
FGFR3-R AGCCAGCAGTTTCTTATCC GAPDH-F GACCCCTTCATTGACCTCAACTA GAPDH-R AAGTTGTCATGGATGACCTTGGC
OCN-F GCCCTGACTGCATTCTGCCTCT
OCN-R TCACCACCTTACTGCCCTCCTG OPN-F CTGCCAGCACACAAGCAGAC OPN-R TCTGTGGCATCGGGATACTG
| RE SULTS
| Exogenous mutant hFGF23(A12D) was overexpressed in RC cells and failed to be secreted
To validate whether mutant hFGF23(A12D) affects osteoblast genesis, we isolated RC cells, osteogenic progenitor cells, from SD rats. First, we constructed pLVX-hFGF23-mCMV-ZsGreen and pLVX-hFGF23(A12D)-mCMV-ZsGreen and obtained the correct insert sequences ( Figure 1A ). We also prepared recombinant lenti- Figure 1C and D, overexpression of hFGF23(A12D) and hFGF23-WT was successfully achieved. As shown in Figure 1E , the ELISA assay showed that secreted hFGF23 was significantly increased in the overexpression cells; however, secreted hFGF23 in the hFGF23(A12D) group showed no significant difference from the control. Together, these observations suggest that both mutant hFGF23(A12D) and hFGF23-WT are overexpressed in RC cells, but hFGF23(A12D) fails to be secreted.
| Mutant hFGF23(A12D) inhibits proliferation ability of RC cells
Given that RC cells can be induced to differentiate into osteoblasts, 9 we considered whether mutant hFGF23(A12D) would have an influence on RC cells. In order to determine the effect of mutant hFGF23(A12D) on cell proliferation ability, we performed the CCK-8 assay in rLV-mCMV-ZsGreen, hFGF23(A12D) and hFGF23-WT cells.
As shown in Figure 2A , on the first and second day, cell growth ability was not different among the three groups. From the third day up to the sixth day, cell proliferation was significantly decreased in the hFGF23(A12D) group, whereas the hFGF23-WT group showed no significant difference from the control, except on day 4 when the proliferation of hFGF23-WT cells was significantly higher than that of control cells ( Figure 2B ).
Taken together, these results indicate that mutant hFGF23(A12D)
inhibits the proliferation ability of RC cells, while hFGF23-WT does not. The inhibition could owe to cell transformation and differentiation ( Figure S1 ). show that mutant hFGF23(A12D) significantly increases ALP expression. E, Alizarin red staining was performed at day 21 and shows that the quantitation of mineralization nodules shows no significant alteration in the hFGF23-A12D group and is significantly decreased in the hFGF23-WT group. F, After osteoblasts were induced from RC cells, alizarin red staining was performed at day 21. The result shows that hFGF23(A12D) inhibits matrix mineralization compared to control group, while it increases matrix mineralization compared to hFGF23-WT. *P < 0.05 and **P < 0.01 vs control group. ## P < 0.01 vs hFGF23(A12D) group. Values are presented as mean ± SD fold change Furthermore, we detected matrix mineralization by Alizarin red staining (stains calcium nodules) on day 21 in induced osteoblasts from these groups. As shown in Figure 2E , the number of Alizarin red-positive calcium nodules was not significantly altered between the hFGF23(A12D) group and the rLV-mCMV-ZsGreen control group. However, the number of calcium nodules in the hFGF23-WT group was significantly decreased compared to the rLV-mCMVZsGreen control. Moreover, we induced osteoblasts from RC cells and then infected osteoblasts with rLV-mCMV-ZsGreen, hFG-F23(A12D) or hFGF23-WT. As shown in Figure 2F , the number of Alizarin red-positive calcium nodules in both the hFGF23(A12D) and hFGF23-WT groups was significantly decreased compared to the rLV-mCMV-ZsGreen control. Moreover, the number of Alizarin red-positive calcium nodules in the hFGF23(A12D) group was significantly increased compared to the hFGF23-WT group. Together, these findings suggest that hFGF23(A12D) can stimulate differentiation from RC cells to osteoblasts and inhibit matrix mineralization.
In contrast, hFGF23-WT can inhibit both differentiation and matrix mineralization.
| Mutant hFGF23(A12D) activates MAPK signalling pathway and increases FGFR3 expression during osteoblast differentiation in RC cells
In order to determine how mutant hFGF23(A12D) influences osteoblast differentiation, we performed RNA-sequence analysis of the induced osteoblasts. As shown in Figure 3A and Table 2 Together, these observations suggest that mutant hFGF23(A12D)
activates the MAPK signalling pathway and increases FGFR3 expression during osteoblast differentiation from RC cells.
| Mutant hFGF23(A12D) activates MAPK signalling pathway through interaction with intracellular domain of FGFR3
Given that our results showed that mutant hFGF23(A12D) can activate the FGFR3-dependent MAPK signalling pathway, and mutant hFGF23(A12D) failed to be secreted by osteoblasts, we considered whether hFGF23(A12D) may function through the FGFR3 intracellular domain. First, we performed a bioinformatics analysis to predict whether the hFGF23(A12D) protein could bind to the intracellular domain of FGFR3. As shown in Figure 4A , results showed that the predicted value of Delta G (binding free energy) for the binding of the 
| D ISCUSS I ON
It is well known that hFGF23 belongs to a subfamily of mammalian endocrine FGFs, which can reduce phosphate reabsorption and suppress the production of 1,25(OH)2D through reduction of 1α-hydroxylase. 13 However, the function of mutant FGFs has not been clearly defined.
Here, we clearly demonstrate that mutant hFGF23(A12D) stimulates the differentiation of RC cells to osteoblasts through the MAPK signalling pathway via FGFR3 activation, which interacts with hFGF23(A12D) through its intracellular cytoplasmic tyrosine kinase domain ( Figure 4D ). In this study, for the first time, we have identified a non-secretory mutant hFGF23(A12D), which plays an important role in osteoblast differentiation. This suggests that the function of mutant hFGF23(A12D) during RC cell differentiation is different from wild-type FGF23. We postulated that this is related to the mutation of A12D, which is located in the hydrophobic core of the signal peptide, and blocks hFGF23(A12D)
secretion. Conversely, a previous study showed that hFGF23 also inhibited osteoblast mineralization through FGFR1c, 9 while our results showed that compared to hFGF23, mutant hFGF23(A12D)
less slightly inhibited mineralization in osteoblasts, which suggests that mutant hFGF23(A12D) is involved in osteoblast mineralization through a different pathway than hFGF23-WT.
Our study also suggests that mutant hFGF23(A12D) inhibited 
14,15
For example, FGF23 binds to FGFR1c, FGFR3c and FGFR4 in vitro and the effect of FGF23 on vitamin D metabolism may be mediated through FGFR3. 16 Study revealed that FGF23 can stimulate osteoblast proliferation and inhibit mineralization through FGFR1
in the presence of alpha-Klotho. 10 We predicted that the difference in secondary structure ( Figure S4 ) between hFGF23-WT and hFGF23(A12D) may result in novel functions. Therefore, we suggested that mutant hFGF23(A12D) can bind to certain intracellular signalling molecules. Notably, the results of bioinformatics analysis, co-IP and immunofluorescence staining revealed that mutant hFGF23(A12D) interacts with the intracellular domain of FGFR3. Therefore, we have reason to consider that the non-secretory mutant hFGF23(A12D) functions through intracellular action.
FGFR3 is one of a family of four membrane-bound tyrosine kinase receptors, largely expressed in cartilage and bone, 17 consisting of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. 18 Moreover, previous studies have demonstrated FGFR3 to be a negative regulator of bone growth, which can activate downstream signalling pathways. 19 Of significance, FGFR3-/-murine bones show severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth. 20 In particular, FGFR3 inhibits chondrocyte proliferation in vitro through activating STAT-1 21 and also regulates the proliferation, osteogenic differentiation and matrix mineralization of BMSCs through ERK1/2 and p38 MAPK pathways. 22 A study also suggests FGF23 binds to FGFR3 and then activates FGFR3, which may suppress chondrocyte proliferation through FGFR3. 14, 23 Notably, the function of mutant hFGF23(A12D) is similar to the phenotype expressed by FGFR3 activation. Taken together, our results suggest that hFGF23(A12D) may stimulate differentiation from RC cells to osteoblasts through activating the MAPK signalling pathway through interactions with the intracellular domain of FGFR3.
Similar to heterozygous mice (FGF23+/-), there were no significant differences in serum levels of FGF23 in MP patients.
However, heterozygous mice showed no significant differences in appearance, 8 while MP patients show no significant differences in appearance except the overgrowth of mandible compared to maxilla. Firstly, although a part of hFGF23-WT is replaced by hFGF23 In conclusion, we demonstrated that compared to hFGF23- 
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